ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,127.79
1.26%
Dow Jones
38,675.68
1.18%
US Dollar vs MXN
16.9724
0.00%
Brent Oil
82.765
0.00%
Bitcoin
62,695.61
-0.31%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. ALX Oncology Holdings Inc (ALXO)

  7. ALX Oncology Holdings Inc (ALXO) Noticias

ALXO ALX Oncology Holdings Inc

15.36
-1.26 (-7.58%)
03 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
ALX Oncology Holdings Inc ALXO NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-1.26 -7.58% 15.36 15:46:57
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
16.92 15.2144 17.13 15.36 16.62
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
30/4/202408:00GLOBEALX Oncology Announces Initiation of Phase 2..
24/4/202409:00GLOBEALX Oncology Announces Two Evorpacept Abstracts Accepted for..
09/4/202416:30GLOBEALX Oncology Reports Encouraging Clinical Data of Evorpacept..
07/3/202415:05EDGAR2Form 8-K - Current report
07/3/202415:03GLOBEALX Oncology Reports Fourth Quarter and Full Year 2023..
05/3/202415:30GLOBEALX Oncology Announces Two Evorpacept Clinical Abstracts..
16/2/202417:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202417:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202417:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202415:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202415:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202407:00GLOBEALX Oncology to Present at the 42nd Annual J.P. Morgan..
26/12/202315:01EDGAR2Form 8-K - Current report
13/11/202315:05GLOBEALX Oncology Reports Third Quarter 2023 Financial Results..
13/11/202315:03EDGAR2Form 8-K - Current report
01/11/202315:05GLOBEALX Oncology Announces November Investor Conference..
10/10/202315:05GLOBEALX Oncology Announces Closing of Public Offering, Including..
06/10/202305:06EDGAR2Form 8-K - Current report
06/10/202305:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/10/202307:00GLOBEALX Oncology Announces Pricing of Public Offering
04/10/202316:21EDGAR2Form 8-K - Current report
04/10/202316:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/10/202315:10GLOBEALX Oncology Announces Proposed Public Offering
04/10/202307:00EDGAR2Form 8-K - Current report
03/10/202309:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202305:00GLOBEALX Oncology Reports Positive Interim Phase 2 ASPEN-06..
02/10/202315:05GLOBEALX Oncology to Host Investor Call and Webcast on October 3,..
20/9/202307:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
10/9/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
08/9/202315:25EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202315:05EDGAR2Form 8-K - Current report
06/9/202307:00GLOBEALX Oncology Realigns Executive Leadership Team
01/9/202315:11EDGAR2Form S-3 - Registration statement under Securities Act of..
31/8/202306:00GLOBEALX Oncology Announces September Investor Conference..
25/8/202315:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/8/202315:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202315:05EDGAR2Form 8-K - Current report
10/8/202315:01GLOBEALX Oncology Reports Second Quarter 2023 Financial Results..
27/7/202315:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202315:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202315:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/7/202315:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202316:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202316:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/7/202316:05EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/6/202306:00GLOBEALX Oncology Receives Orphan Drug Designation from the..
11/5/202315:01GLOBEALX Oncology Reports First Quarter 2023 Financial Results..
09/5/202306:00GLOBEALX Oncology Announces First Patient Dosed in Phase 2..

Su Consulta Reciente

NASDAQ
ALXO
ALX Oncology
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados